Seedlabs

First-Event PCSK9i Coverage Criteria Pack

A set of insurance rules that allow patients without a history of heart attack to get coverage for cholesterol injections.

A ready-to-deploy prior-authorization policy module for PBMs and health plans that adds the newly proven 'no prior heart attack or stroke' population to PCSK9-inhibitor coverage, with documentation guardrails and a budget-impact model that offsets drug spend with avoided artery-opening procedures.

MedicineLipoproteins and Cardiovascular Health
Attention Deficit Hyperactivity DisorderPayer/PBM pharmacy benefit management — PCSK9-inhibitor prior-authorization policy

Concept

A utilization-management policy module for PBMs and health plans that rewrites PCSK9-inhibitor prior-authorization criteria to cover the newly proven population: patients with documented atherosclerosis or diabetes, no prior myocardial infarction or stroke, and LDL cholesterol ≥90 mg/dL on maximally tolerated statin therapy. The pack ships (a) updated PA criteria language with documentation guardrails (imaging-confirmed atherosclerosis or a diabetes diagnosis plus a qualifying LDL lab), (b) an appeals-ready evidence summary citing the trial, and (c) a budget-impact model that sizes the newly eligible membership and offsets drug cost with avoided ischemia-driven revascularizations, which are part of the trial's primary endpoint.

Why now

[0] is the first placebo-controlled evidence (12,257 patients, median 4.6-year follow-up) that a PCSK9 inhibitor lowers the risk of first cardiovascular events in patients without prior MI or stroke: 3-point MACE HR 0.75 and 4-point MACE HR 0.81, both P<0.001, with no evidence of a between-group difference in safety events. Existing PA criteria — written around established ASCVD or familial hypercholesterolemia — are now out of date and vulnerable on appeal. The 4-point endpoint (5-year Kaplan-Meier 13.4% vs 16.2%) explicitly includes ischemia-driven arterial revascularization, giving plans a concrete procedure-cost offset to model against drug spend. The AHA's 2026 statistics report [6] supplies the population denominators (cholesterol, diabetes, and cardiovascular risk-factor prevalence) needed to size the budget impact credibly.

Written by GLM · 12 Oct 2026

AI assessment

Backed by 2 papers88

A highly focused, evidence-backed policy product that solves a specific regulatory and financial pain point for PBMs using a high-quality clinical trial.

Evidence strength
5/5
The idea is directly derived from a large-scale, placebo-controlled trial with a 4.6-year follow-up and clear primary endpoints (3-point and 4-point MACE) that specifically support the target population.
Market pull
4/5
PBMs and health plans have a strong incentive to update PA criteria to avoid appeals and optimize spend, though the 'buyer' is a corporate policy committee rather than a traditional software user.
Novelty & moat
3/5
While it shares the same target population as the 'Silent-Plaque Finder', it shifts the value proposition from clinical identification to payer policy and financial modeling.
Feasibility
5/5
The product is essentially a set of documents, criteria language, and a spreadsheet model, requiring very little technical development to deliver a prototype.
Wedge clarity
5/5
The wedge is extremely sharp: updating a specific drug's coverage criteria for a specific newly-proven patient cohort.
Simplicity / focus
5/5
It avoids 'platform' creep by focusing on a single drug class and a single policy update package.

Scored by Gemma 4 · 12 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Amgencompany

    Expanded, criteria-backed access to the event-free atherosclerosis/diabetes population is the direct commercial payoff of the trial it funded.

  • CVS Caremarkcompany

    One of the largest PBMs managing PCSK9i prior authorizations; it needs defensible, evidence-current criteria the day first-event data changes the coverage standard.

  • Evernorth (Express Scripts)company

    Manages pharmacy benefits for tens of millions of members; the pack's ready-made criteria plus budget-impact model directly supports its formulary and UM decisions.

  • UnitedHealthcarecompany

    Bears both drug spend and downstream MI/stroke/revascularization costs; the revascularization offset in the model maps to real procedure dollars it pays for.

Research it builds on

  1. 2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
    Latha P Palaniappan, Norrina B. Allen, Zaid Almarzooq et al. · 2026 · 223 citations
    All ideas from this paper →
  2. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke
    Erin Ann Bohula, Nicholas Marston, Ajay K. Bhatia et al. · 2025 · 112 citations
    All ideas from this paper →
Leave feedback
feasibility